Rani Therapeutics Holdings, Inc. Net Income Loss

• Rani Therapeutics Holdings, Inc. showed an increase of +1.1% in Net Income Loss from 2024 to 2025.
• This data is from Rani Therapeutics Holdings, Inc.'s annual report (Form 10-K), filed with the SEC on March 26, 2026.
• XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 5 years of available data (2021 to 2025), Rani Therapeutics Holdings, Inc.'s Net Income Loss has declined by 256.2%.
• Historical annual values: Fiscal year 2025: -$29.67 million | Fiscal year 2024: -$30.02 million | Fiscal year 2023: -$33.97 million | Fiscal year 2022: -$30.59 million | Fiscal year 2021: -$8.33 million.
• Data sourced from SEC EDGAR public filings as of June 22, 2026.

Last verified: June 22, 2026